Phase 3 Multicenter Comparative Study to Confirm Safety and Effectiveness of the F(ab)2 Antivenom Anavip.
A Comparison of Anavip® and CroFab® in the Treatment of Patients With Crotalinae Envenomation: A Randomized, Prospective, Blinded, Controlled, Comparative, Multicenter Study
Sponsor: Instituto Bioclon S.A. de C.V.
Listed as NCT00636116, this PHASE3 trial focuses on Snake Bite and remains completed. Sponsored by Instituto Bioclon S.A. de C.V., it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Instituto Bioclon S.A. de C.V.
- Universidad Nacional Autonoma de Mexico
- University of Arizona
For direct contact, visit the study record on ClinicalTrials.gov .